What is a stock summary page? Click here for an overview.
Business Description
Sage Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US78667J1088
Compare
Compare
Traded in other countries / regions
SAGE.USASG7.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2014-07-18Description
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 42.62 | |||||
| Equity-to-Asset | 0.85 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -5.07 | |||||
| Beneish M-Score | -4.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 84.6 | |||||
| 3-Year EBITDA Growth Rate | 4.7 | |||||
| 3-Year EPS without NRI Growth Rate | 7.2 | |||||
| 3-Year FCF Growth Rate | 12 | |||||
| 3-Year Book Growth Rate | -36.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 35.92 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 54.94 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 84.02 | |||||
| 9-Day RSI | 76.8 | |||||
| 14-Day RSI | 72.28 | |||||
| 3-1 Month Momentum % | 25.13 | |||||
| 12-1 Month Momentum % | -61.49 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.42 | |||||
| Quick Ratio | 7.42 | |||||
| Cash Ratio | 7.04 | |||||
| Days Payable | 349.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.3 | |||||
| Shareholder Yield % | -1.33 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 77.1 | |||||
| Operating Margin % | -995.36 | |||||
| Net Margin % | -971.48 | |||||
| FCF Margin % | -647.85 | |||||
| ROE % | -63.59 | |||||
| ROA % | -56.97 | |||||
| ROIC % | -1091.7 | |||||
| 3-Year ROIIC % | -270.17 | |||||
| ROC (Joel Greenblatt) % | -5513.55 | |||||
| ROCE % | -64.73 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 12.7 | |||||
| PB Ratio | 1.13 | |||||
| Price-to-Tangible-Book | 1.13 | |||||
| EV-to-EBIT | -0.08 | |||||
| EV-to-EBITDA | -0.08 | |||||
| EV-to-Forward-EBITDA | -0.1 | |||||
| EV-to-Revenue | 0.77 | |||||
| EV-to-Forward-Revenue | 0.45 | |||||
| EV-to-FCF | -0.12 | |||||
| Price-to-GF-Value | 0.07 | |||||
| Price-to-Net-Current-Asset-Value | 1.17 | |||||
| Price-to-Net-Cash | 1.25 | |||||
| Earnings Yield (Greenblatt) % | -1250 | |||||
| FCF Yield % | -50.53 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SAGE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sage Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 41.243 | ||
| EPS (TTM) ($) | -6.59 | ||
| Beta | 0.24 | ||
| 3-Year Sharpe Ratio | -0.85 | ||
| 3-Year Sortino Ratio | -0.99 | ||
| Volatility % | 55.02 | ||
| 14-Day RSI | 72.28 | ||
| 14-Day ATR ($) | 0.30676 | ||
| 20-Day SMA ($) | 7.6765 | ||
| 12-1 Month Momentum % | -61.49 | ||
| 52-Week Range ($) | 4.62 - 19.34 | ||
| Shares Outstanding (Mil) | 61.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sage Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sage Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sage Therapeutics Inc Frequently Asked Questions
What is Sage Therapeutics Inc(SAGE)'s stock price today?
The current price of SAGE is $8.60. The 52 week high of SAGE is $19.34 and 52 week low is $4.62.
When is next earnings date of Sage Therapeutics Inc(SAGE)?
The next earnings date of Sage Therapeutics Inc(SAGE) is 2025-04-25 Est..
Does Sage Therapeutics Inc(SAGE) pay dividends? If so, how much?
Sage Therapeutics Inc(SAGE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers